We are a Chinese biopharmaceutical enterprise focusing on the discovery and development of innovative and differentiated antibody drugs, and strive to become an international biopharmaceutical company with core products and sustainable innovation capabilities. Our mission is to translate scientific breakthroughs in immunology and biology into novel targeted antibody therapies, covering the biopharmaceutical markets for autoimmune diseases and tumors — markets that are rapidly expanding globally and in China with largely unmet clinical demands. We will seize this opportunity to continuously deliver innovative and affordable treatment regimens for patients in these fields.
Building on our strong foundation in biomedical research, we have developed in-house proprietary antibody discovery and development technology platforms, including the ADCC-enhanced antibody platform, the multispecific antibody platform, the half-life extended antibody platform, the antibody discovery and optimization platform and the process development and industrialization platform. Our ADCC-enhanced antibody platform is one of the leading platforms in the world to enhance NK-cell function through antibody glycosylation modification. It also meets GMP manufacturing standards in China and has undergone clinical validation. Our multi-specific antibody platform enables us to develop antibodies simultaneously binding to different targets to achieve synergistic therapeutic functions. Our half-life extended antibody platform integrates advanced antibody engineering technologies to optimize the pharmacokinetic properties of antibodies, enabling longer dosing intervals and thereby enhancing patient compliance in treatment. Our antibody platforms encompass the entire process from antibody discovery to development, enabling us to efficiently design, evaluate, select and develop the most promising drug candidates.
By leveraging our proprietary antibody R&D platforms, we have developed a differentiated pipeline, including an approved product and multiple clinical-stage or preclinical drug candidates. Our core product, Bejescin® (MIL62), is a novel 3rd-generation anti-CD20 monoclonal antibody and has been approved by NMPA for marketing in China for the treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD) and Primary Membranous Nephropathy (PMN). It is the world’s first drug granted approval for the pMN indication, as well as the first domestic drug approved for the NMOSD indication in China.
MBS303/MSC303 is a novel CD20/CD3 T-cell engager (TCE) with the potential to benefit a wide range of patients with immune-mediated glomerulonephritis and hematological malignancies. MBS314 is a novel GPRC5D/BCMA/CD3 TCE providing a potentially superior solution for patients with multiple myeloma. MIL116 is a novel anti-APRIL antibody that offers a more effective and convenient potential treatment option for patients with IgA nephropathy.
Our industry leading antibody R&D, manufacturing and commercialization capabilities have been recognized and validated through various strategic collaborations with leading pharmaceutical companies in China and globally. We have established partnerships with our partners at various stages. We anticipate that these partnerships will create substantial synergy with our internal R&D efforts and help us maximize the clinical and commercial value of our products.
